WELLESLEY HILLS, Mass., March 1, 2011 /PRNewswire/ — Source
Precision Medicine, Inc., dba SourceMDx (“SourceMDx”) has assigned
all its assets to Joseph F. Finn, Jr., C.P.A. (“Finn”) of the firm
Finn, Warnke & Gayton, LLP to be liquidated for the benefit of
Source MDx® is an industry leader in developing simple blood
tests that can consistently detect the presence and aggressiveness
of cancer by measuring specific RNA transcripts in blood. RNA is an
early biological measure of disease, providing a significant
indicator of disease onset or progression in the blood stream
before other clinical manifestations become observable. Source
MDx® is the first to translate robust RNA-transcript based
assays into clinically useful oncology molecular diagnostic tests
using a simple, non-invasive blood test. Source MDx® tests are
precise and calibrated measurements of white blood cell gene
expression and track an individual’s current health, disease status
and response to therapy in a reproducible fashion.
The intellectual property, patents, etc. will be sold at a
sealed bid sale on Friday, April 29, 2011 at noon.
Persons interested in bidding must sign a Confidentiality
Disclosure Agreement (“CDA”) obtained from Finn’s Office –
email@example.com or 781-237-8840. They will then
receive a bid package.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm,
Finn, Warnke & Gayton (www.finnwarnkegayton.com),
Certified Public Accountants of Wellesley Hills, Massachusetts. He
works primarily in the area of management consulting for distressed
enterprises, bankruptcy accounting and related matters, such as
assignee for the benefit of creditors and liquidating agent for a
corporation. He has been involved in a number of loan workouts and